Company Profile

Oscilloscape LLC (AKA: Oscillo Biosciences )
Profile last edited on: 10/11/2021      CAGE: 4DC85      UEI: CPDCLG55B5Z3

Business Identifier: Music-based therapeutic solutions for the treatment of neurological disorders
Year Founded
2016
First Award
2020
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

222 Pitkin Street
Hartford, CT 06108
   (860) 282-4215
   info@oscilloscape.com
   www.oscilloscape.com
Location: Single
Congr. District: 01
County: Hartford

Public Profile

Oscilloscape LLC, aka Oscillo Biosciences, is developing solutions using music and light to preserve and restore memory and cognition in individuals with Alzheimer's disease and related dementias. The company's primary product, SynchronyGamma, synchronizes music in a way that stimulates brain activity, naturally activating memory, emotion, and reward centers while also using light to produce changes in the brain at a molecular level. The company aims to use this technology to delay or reverse the onset of dementia-related disorders like Alzheimer's disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
0
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $449,695
Project Title: SynchronyGamma: a Music-Based Intervention for Alzheimer's and Mild Cognitive Impairment
2020 1 NSF $224,846
Project Title: SynchronyGamma ? a Music-Based Intervention for Alzheimer?s and MCI

Key People / Management

  Michael Canzian -- CEO

  Mark Costanzo -- CFO

  Ji Chul Kim -- co-founder and CSO

  Ed Large -- co-founder and Chief Innovation Officer

Company News

There are no news available.